TRON Group Inc (TGRP) Gagner

TRON Group, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development of oral, topical, and injectable products for cancer, central nervous system disorders, diabetes, and infectious diseases. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan and currently employs 50 full-time employees. The company went IPO on 2016-06-22. The Company, through its subsidiaries, is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. Its pipeline includes nine clinical-stage proprietary and partnered programs, including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; PRX-3140 targeting diabetes; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability.